Tenderwize
Retour à la recherche

Open-house rebate agreements for Xipamid

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jan 03, 2028 · 492 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Xipamid, ATC C03BA10

58/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

58 / 100

Complexité

42 / 100

Facteurs de risque

The notice says the model is open-house and not subject to ordinary procurement selection logic, which may affect legal...

Documents must be submitted through the DTVP communication area, not the offer area; paper originals must be in duplica...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Non-exclusive pharmaceutical rebate agreements for the active substance Xipamid (ATC C03BA10).
  • Open-house model with identical, pre-set contract terms and no individual negotiation.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement for Xipamid (ATC C03BA10) led by AOK Bayern. It is not a competitive award procedure in the usual sense: all interested pharmaceutical companies that meet the stated eligibility condition can join on identical, non-negotiable terms. The contract period runs from 01.03.2026 to 29.02.2028, with contract entry possible until 03.01.2028. Submission is via DTVP electronic portal with a qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents must be submitted with German translation.

Risques

The notice says the model is open-house and not subject to ordinary procurement selection logic, which may affect legal...

Documents must be submitted through the DTVP communication area, not the offer area; paper originals must be in duplica...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract and annex 'Determination of the contract products' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for Xipamid

Open-house supply arrangement for pharmaceutical rebate agreements concerning Xipamid (ATC C03BA10). The lot is described as a non-exclusive, identical, non-negotiable contract model for all eligible pharmaceutical companies. Performance is in Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Feb 2026 - Feb 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 03, 2028

Détails de la procédure

Date de publication
13 Jan 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
23964-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30